New Data on Multiple Bristol-Myers Squibb Investigational Hepatitis C Compounds to be Presented at The International Liver

Data Demonstrate Focused Execution of the Company’s Hepatitis C R&D Strategy

PRINCETON, N.J.--(BUSINESS WIRE)-- New Phase II data on multiple Bristol-Myers Squibb Company (NYSE: BMY) investigational hepatitis C compounds will be presented at The International Liver Congress (ILC), the 46th annual meeting of the European Association for the Study of the Liver (EASL) in Berlin, Germany, from March 30 to April 2. The data presentations, including three late-breaker presentations, demonstrate the rigorous execution of the company’s strategy to develop potential improvements in the care of patients living with Hepatitis C infection by using multiple approaches to target the virus.

Bristol-Myers Squibb will present three late-breaker presentations, including a poster presentation of the first public disclosure of 12-week data on sustained virologic response (SVR) with the NS5A inhibitor BMS-790052 in combination with PEG-Interferon alpha-2a and ribavirin (IFNα/RBV) in treatment-naïve HCV patients. Additionally, SVR 12-week data on quadruple therapy with BMS-790052, the NS3 inhibitor BMS-650032 and IFNα/RBV in null responders will be presented in the late-breaker oral presentation session on Saturday, April 2. Complete early virology response (cEVR) data from the Phase IIb EMERGE study of PEG-Interferon lambda and ribavirin versus IFNα/RBV in treatment-naïve patients will also be presented in a late-breaker oral presentation.

“Bristol-Myers Squibb is focused on advancing the science to address significant unmet medical needs for patients with liver disease,” said Brian Daniels, MD, senior vice president, Global Development and Medical Affairs, Research and Development, Bristol-Myers Squibb. “The data at the International Liver Congress reflect the breadth of our hepatitis C pipeline and the multiple approaches we are taking to bring forward potential new options for a disease that today impacts approximately 170 million people worldwide.”

BMS-790052 and BMS-650032 were discovered by Bristol-Myers Squibb Research and Development. PEG-Interferon lambda was discovered by ZymoGenetics, Inc., a wholly-owned subsidiary of Bristol-Myers Squibb.

The Bristol-Myers Squibb data presentations at ILC are as follows:

Date/Time   Presentation Title   Lead Author
March 31  

First report of SVR12 for a NS5A Replication complex inhibitor, BMS-790052 in combination with PEG-IFNα-2A and RBV: Phase 2a trial in treatment-naïve HCV-Genotype 1 subjects (Poster Board # 1373)

  S. Pol

Hôpital Cochin

Paris, France

April 1  

In Vitro DAA combination studies to address HCV clinical findings (Poster Board # 803)

  J.A. Lemm

Bristol-Myers Squibb

April 1  

BMS-766, A Novel HCV NS5a inhibitor with enhanced resistance coverage (Poster Board # 787)

  M. Gao

Bristol-Myers Squibb

April 1,

4:45 –5:00 p.m.

  Characterization of Virologic Escape in

HCV Genotype 1 Null responders

receiving a combination of the NS3 protease inhibitor BMS-650032 and NS5A inhibitor BMS-790052 (Oral Session)

  F. McPhee

Bristol-Myers Squibb

April 2  

BMS-650032, an NS3 inhibitor, in combination with Peginterferon Alfa-2a and Ribavirin in treatment-naïve subjects with genotype-1 chronic hepatitis C infection (Poster Board # 1195)

  J. Bronowicki

Hôpital Adultes De Brabois

Vandoeuvre Les Nancy, France

April 2  

No early virologic breakthrough observed with the HCV NS3 protease inhibitor BMS-650032 in multiple dose monotherapy studies and Phase 2a combination studies with PEG-INF alpha/RBV (Poster Board # 1223)

  F. McPhee

Bristol-Myers Squibb

April 2  

The burden of hepatitis C in Europe: a propensity analysis of patient outcomes (Poster Board # 1192)

  M. daCosta DiBonaventura

Kantar Health

New York, New York

April 2  

Estimating the incidence and prevalence of hepatitis C infection in England using back projection methods (Poster Board # 1166)

  P. McEwan

Cardiff Research Consortium

Cardiff, UK

Swansea University

Swansea, UK

April 2  

Cost benefit analysis of response guided therapy: dynamic disease Markov modeling for patients with chronic hepatitis (HCV) by fibrosis stages (Poster Board # 1167)

 

P. McEwan

Cardiff Research Consortium

Cardiff, UK

Swansea University

Swansea, UK

April 2,

3:30 – 5:30 p.m.

  Pegylated Interferon-Lambda (PEGIFN-λ) shows superior viral response with improved safety and tolerability versus PEGIFNα-2A in HCV patients (G1/2/3/4): EMERGE Phase IIb through week 12 (Late-Breakers Oral Session)   S. Zeuzem

Klinikum der Johann-Wolfgang Goethe-Universität, Frankfurt/Main, Germany

April 2,

3:30 – 5:30 p.m.

  Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in HCV Genotype 1 null responders (Late-Breakers Oral Session)   A. Lok

University of Michigan

Ann Arbor, Michigan

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.



CONTACT:

Bristol-Myers Squibb
Media:
Cristi Barnett, 609-252-6028
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Infectious Diseases  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.